|
381 |
Methodological Concerns with Economic Evaluations of Meningococcal Vaccines
Enthalten in PharmacoEconomics Bd. 28, 17.9.2012, Nr. 6, date:6.2010: 449-461
|
|
|
|
382 |
Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands
Enthalten in PharmacoEconomics Bd. 30, 11.10.2012, Nr. 3, date:3.2012: 219-227
|
|
|
|
383 |
Methods of Model Calibration
Enthalten in PharmacoEconomics Bd. 28, 18.10.2012, Nr. 11, date:11.2010: 995-1000
|
|
|
|
384 |
Micafungin
Enthalten in Drugs Bd. 72, 25.12.2012, Nr. 16, date:12.2012: 2141-2165
|
|
|
|
385 |
Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials
Enthalten in Clinical pharmacokinetics Bd. 51, 30.9.2012, Nr. 4, date:4.2012: 261-275
|
|
|
|
386 |
Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France
Enthalten in PharmacoEconomics Bd. 28, 14.10.2012, Nr. 1, date:12.2010: 183-197
|
|
|
|
387 |
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease
Enthalten in PharmacoEconomics Bd. 29, 11.10.2012, Nr. 12, date:12.2011: 1025-1049
|
|
|
|
388 |
Modelling the Epidemiology of Infectious Diseases for Decision Analysis
Enthalten in PharmacoEconomics Bd. 29, 23.12.2012, Nr. 5, date:5.2011: 371-386
|
|
|
|
389 |
Mogamulizumab
Enthalten in Drugs Bd. 72, 6.1.2012, Nr. 9, date:9.2012: 1293-1298
|
|
|
|
390 |
Molecular Targeted Therapy in Ovarian Cancer
Enthalten in Drugs Bd. 71, 27.11.2012, Nr. 8, date:5.2011: 947-967
|
|
Administration
